EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Study Assessing Use of Mood Stabilizers (Sodium Valproate and Oxcarbazepine) as an Augmentation Strategy in Patients of Treatment-resistant Depression

Priya Chugh, Fiona Mahapatro

Annals of Indian Psychiatry · 2025

DOI: 10.4103/aip.aip_107_24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Indian Psychiatry, 2025. Verfasst von Priya Chugh und 1 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment-resistant depression (TRD) is a major challenge, with a significant proportion of patients failing to achieve remission with initial antidepressant treatment. As per literature, augmentation strategies using nonantidepressant agents have been explored to overcome partial or lack of response. This study aimed to determine the efficacy of adding mood stabilizers, sodium valproate, and oxcarbazepine as augmenting agents in patients with TRD. Methodology: This prospective and observational study recruited 106 patients with TRD from a tertiary care center in Navi Mumbai, India. Patients were augmented with either sodium valproate ( n = 53) or oxcarbazepine ( n = 53) in addition to their ongoing antidepressant and anti-anxiety medications. The Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A) were administered at baseline, at 2 weeks, and at 4 weeks after augmentation. Treatment response was documented, and results were statistically analyzed.

Results

Both augmentation groups showed significant improvements in HAM-D and HAM-A scores at 2 and 4 weeks compared to baseline ( P < 0.001). However, the sodium valproate group demonstrated superior efficacy, with a greater reduction in HAM-D scores as compared to the oxcarbazepine group at 2 weeks (25.60 vs. 21.98, P = 0.001) and 4 weeks (34.06 vs. 30.64, P = 0.001).

Conclusion

The addition of mood stabilizers, sodium valproate, and oxcarbazepine, as augmentation agents led to significant improvement in patients with TRD. Sodium valproate exhibited superior efficacy as compared to oxcarbazepine, suggesting its potential as a valuable augmentation strategy in the management of TRD.

Zitieren

APA

Chugh, P., & Mahapatro, F. (2025). Study Assessing Use of Mood Stabilizers (Sodium Valproate and Oxcarbazepine) as an Augmentation Strategy in Patients of Treatment-resistant Depression. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_107_24

Vancouver

Chugh P, Mahapatro F. Study Assessing Use of Mood Stabilizers (Sodium Valproate and Oxcarbazepine) as an Augmentation Strategy in Patients of Treatment-resistant Depression. Annals of Indian Psychiatry. 2025. doi:10.4103/aip.aip_107_24

BibTeX
@article{Chugh2025,
  author = {Chugh, Priya and Mahapatro, Fiona},
  title = {Study Assessing Use of Mood Stabilizers (Sodium Valproate and Oxcarbazepine) as an Augmentation Strategy in Patients of Treatment-resistant Depression},
  journal = {Annals of Indian Psychiatry},
  year = {2025},
  doi = {10.4103/aip.aip_107_24}
}
Kostenlos starten →